Lipocine
LPCN
29 hedge funds and large institutions have $3.73M invested in Lipocine in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 1 closing their positions.
1,271% more call options, than puts
Call options by funds: $96K | Put options by funds: $7K
0.68% less ownership
Funds ownership: 13.4% → 12.71% (-0.68%)
3% less funds holding
Funds holding: 30 → 29 (-1)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
37% less capital inflows, than outflows
Capital inflows: $351K | Capital outflows: $561K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$120K |
| 2 |
JP Morgan Chase
New York
|
+$81.9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.6K |
| 4 |
Renaissance Technologies
New York
|
+$42.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
J. Goldman & Co
New York
|
-$310K |
| 2 |
Morgan Stanley
New York
|
-$127K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$63.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$23.7K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$10.8K |
LPCN Hedge Fund Activity: Q3 2018 in Review
29 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2018, worth a combined $3.73M — up 0.75% from $3.7M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of LPCN and 0 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 9 added.
The largest buyer was Ameriprise, adding an estimated $120K. The largest seller was J. Goldman & Co, cutting an estimated $310K.
- 29 institutional investors held Lipocine (LPCN) as of Q3 2018, down from 30 in Q2 2018.
- Funds reported $3.73M of Lipocine stock for Q3 2018, up 0.75% quarter-over-quarter.
- 0 funds opened new Lipocine positions in Q3 2018 and 1 closed out, a net change of -1 holder.
- The largest Lipocine buyer in Q3 2018 was Ameriprise, an estimated $120K added.
- The largest Lipocine seller in Q3 2018 was J. Goldman & Co, an estimated $310K sold.
Based on aggregated 13F filings for Q3 2018.